David Thompson
Corporate Officer/Principal bei INOZYME PHARMA, INC.
Profil
David Thompson is the founder of Azure Biotech, Inc. He is currently a Member-Scientific Advisory Board & Senior Advisor at Inozyme Pharma, Inc. His former position at Inozyme Pharma, Inc. was Chief Scientific Officer & Senior Vice President from 2018 to 2020.
Dr. Thompson has a graduate and doctorate degree from the University of Connecticut and a graduate degree from The University of Montana.
Aktive Positionen von David Thompson
Unternehmen | Position | Beginn |
---|---|---|
INOZYME PHARMA, INC. | Corporate Officer/Principal | 01.07.2021 |
Ehemalige bekannte Positionen von David Thompson
Unternehmen | Position | Ende |
---|---|---|
INOZYME PHARMA, INC. | Chief Tech/Sci/R&D Officer | 13.10.2020 |
Azure Biotech, Inc.
Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Founder | - |
Ausbildung von David Thompson
University of Connecticut | Doctorate Degree |
The University of Montana | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
INOZYME PHARMA, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Azure Biotech, Inc.
Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Health Technology |